Review
Ibrutinib: first global approval.
Drugs. 2014 Feb 1;74(2):263-71.
Review
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Cochrane Db Syst Rev. 2012 Sep 12; 2012 (9): CD009045CD009045.
Review
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Leuk. Lymphoma. 2014 Feb 1;55(2):263-9.